A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Mark S. Hertzberg, Matthew Ku, Olivier Catalani, Betsy Althaus, Steven Simko, Gareth Peter Gregory

Research output: Contribution to journalMeeting AbstractOtherpeer-review

Original languageEnglish
Article numberTPS7575
Number of pages1
JournalJournal of Clinical Oncology
Issue number15 suppl
Publication statusPublished - 28 May 2021
EventAmerican Society of Clinical Oncology Annual Meeting 2021 - Online
Duration: 4 Jun 20218 Jun 2021

Cite this